Epigenomics AG Receives Allowance for Key Technology Patent in Japan
Patent broadly covers HeavyMethyl, a core technology of Epigenomics' molecular diagnostic products
The HeavyMethyl(TM) technology allows the specific and highly sensitive detection of methylated DNA in large background of unmethylated DNA using real-time PCR, the current industry technology standard in molecular diagnostics. The technology is currently used in Epigenomics' own in vitro diagnostic products for the early detection and diagnosis of cancer as well as in products of Epigenomics' biomarker and technology licensees.
Most read news
Organizations
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.